Capricor Therapeutics Inc. - CAPR Net Assets per Single Share

Graphic logo of Capricor Therapeutics, Inc. (CAPR)

The current price chart for Capricor Therapeutics (CAPR) illustrates the price action of an asset whose foundation relies on the symbiosis of cell technologies and exosomes to combat heart and muscle pathologies. The indicator stands at 4.25. Patent protection and the final testing stages of the drug Deramiocel provide the company with a competitive advantage. High growth potential is driven by the medical community's increasing demand for innovative therapy for Duchenne muscular dystrophy.

Capricor (CAPR): Share Book Value from 07/04/2022 to 10/27/2026

Capricor Therapeutics Inc. - analytical breakdowns and key metrics (CAPR)

- price and consensus price forecast:
Price Chart Capricor|CAPR - Forecast Levels Chart
- market capitalization data:
Market Value Capricor Therapeutics, Inc.|CAPR - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Capricor Therapeutics|CAPR - Net Asset Value|Market Capitalization to Book Value Ratio capricor.com|CAPR - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Capricor Therapeutics|CAPR - Long-Term Debt to Capital|Short-Term Debt to Equity Capricor|CAPR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Capricor Therapeutics, Inc.
Fundamental company valuation:capricor.com - CAPR
Manufactured products of Capricor

This indicator determines investment stability by measuring net equity minus liabilities on a per-share basis. By analyzing the book value per common share, an investor can discern the actual value of assets, which is critical for Capricor Therapeutics (CAPR) during its resource mobilization period for the certification of dermiocele therapy for Duchenne muscular dystrophy.

Competitors of Capricor Therapeutics (CAPR)

Net Assets per Single Share Jazz Pharma|CYTK: Share Book Value|Net Assets per Single Share PTC Therapeutics, Inc. PTCT|SRRK (scholarrock.com) - Accounting Value of a Share|Net Assets per Single Share Centessa CNTA|Share Book Value Dyne Therapeutics Inc|Edgewise Pharma (EWTX) - Book Value per Share|Accounting Value of a Share Rapport Corp (RAPP)|Book Value per Share ALMS (Alumis Inc.)|zevra.com - Book Value per Share|Net Assets per Single Share Contineum Therapeutics (CTNM)|LRMR: Accounting Value of a Share|TRDA (Entrada) - Net Assets per Single Share|Channel Pharma (PTHS) - Accounting Value per Share|MNOV (MediciNova Inc.) - Book Value per Share|Book Value per Share serinatherapeutics.com (SER)|BioXcel Therapeutics, Inc. (BTAI) - Accounting Value per Share|Accounting Value of a Share PMN (promisneurosciences.com)|APUS - Net Assets per Single Share|Equity per Share AEON Biopharma Inc. AEON|NLSP (NLS Pharma) - Book Value per Share|Bionomics Limited (BNOX) - Net Asset Value per Share|HUGE: Accounting Value per Share|RETA (Reata Pharmaceuticals Inc) - Book Value per Share